Company Description
Ascentage Pharma Group is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies.
Our lead assets, olverembatinib and lisaftoclax, have global potential to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma.
We are the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators.
We have eleven completed or ongoing U.S. and/or international registrational trials, including two that are FDA-regulated, for our five key clinical-stage assets.
| Country | China |
| Founded | 2009 |
| IPO Date | Jan 24, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 600 |
| CEO | Dajun Yang, M.D., Ph.D. |
Contact Details
Address: 68 Xinqing Road Suzhou Industrial Park, Suzhou, Jiangsu China | |
| Phone | +86-512-85557777 |
| Website | ascentage.com |
Stock Details
| Ticker Symbol | AAPG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| IPO Price | $17.25 |
| CIK Code | 0002023311 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dajun Yang, M.D., Ph.D. | Chairman, Chief Executive Officer and Director |
| Yifan Zhai, M.D., Ph.D. | Chief Medical Officer |
| Jin Cao | Head of Finance |
| Raymond Jeffrey Kmetz | Chief Business Officer |
| Thomas J. Knapp | Senior Vice President, General Counsel |
| Marina S. Bozilenko | Director |
| Simon Dazhong Lu, Ph.D. | Director |
| Wei Ren | Director |
| David Sidransky, M.D. | Director |
| Shaomeng Wang, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 24, 2025 | 424B4 | Prospectus |
| Jan 24, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 23, 2025 | EFFECT | Notice of Effectiveness |
| Jan 23, 2025 | CERT | Certification by an exchange approving securities for listing |
| Jan 21, 2025 | 8-A12B | Registration of securities |
| Jan 21, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 27, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Dec 10, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 16, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 27, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |